Returning to PARP Inhibition: Rechallenge with Bevacizumab in Ovarian Cancer.

The KGOG 3056/NIRVANA-R trial demonstrated that niraparib rechallenge combined with bevacizumab may potentially be a promising maintenance strategy in patients with platinum-sensitive recurrent ovarian cancer previously treated with poly(ADP-ribose) polymerase inhibitor (PARPi). With a 68% 6-month progression-free survival rate, this combination may synergistically be able to overcome acquired PARPi resistance, particularly in patients with favorable platinum sensitivity. See related article by Cho et al., p. 2537.